Keybanc Maintains Overweight on IQVIA Holdings, Raises Price Target to $270
Keybanc analyst Donald Hooker maintains IQVIA Holdings (NYSE:IQV) with a Overweight and raises the price target from $260 to $270.
Why Are NRx Pharma Shares Moving Higher On Tuesday Premarket?
Iqvia Holdings Inc (NYSE:IQV) has collaborated with NRx Pharmaceuticals Inc (NASDAQ:NRXP) to provide pharmacovigilance services and medical information in preparation for potential regulatory…
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)
IQVIA And NRx Pharmaceuticals Collaborate On Potential Medical Support For Novel COVID-19 Treatment
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx
Where IQVIA Holdings Stands With Analysts
Within the last quarter, IQVIA Holdings (NYSE:IQV) has observed the following analyst ratings:
Argus Research Maintains Buy on IQVIA Holdings, Raises Price Target to $290
Argus Research analyst Jasper Hellweg maintains IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $260 to $290.
IQVIA Collaborates With HealthCore To ‘Advance Clinical Research Using Real-World Data’
IQVIA™ (NYSE:IQV) announces its strategic collaboration with HealthCore, Inc., a leading real world research organization in the United States, to advance real world evidence (RWE) studies with increased quality
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 183 stocks hit new 52-week highs.
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 77 companies hit new 52-week highs.
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs.